DAWN Company Profile and Key Details

DAWN has shown sold momentum, gaining 6.88% over the past week and 68.19% over the past quarter, though year-to-date performance is up 29.94%. Short-term trend indicators are bearishly aligned (SMA20 -6.13%, SMA50 0.61%, SMA200 31.76%). The stock’s 14-day RSI is 44.94 (neutral), while the ATR of 0.78 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.32% below its high and over 89.0% above its low.

Day One Biopharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $22.93. This means the shares are trading below this model’s fair value.

Day One Biopharmaceuticals, Inc. has 102.43 million shares outstanding. The public float is 78.72 million shares, elevated short interest at 16.30% of float. This equals 11.28 million shares. The short ratio is 5.87 days. Institutional investors hold 103.15% of the float. Insiders own 16.94%. Canaan XI L.P. holds 8.46 million shares, Blackman Samuel C. has 1.03 million shares and AI Day1 LLC has 827.59 thousand shares. Over the past six months, insider transactions show net selling. They sold 36.46 thousand shares across 5 transactions.

The stock is currently trading near its 52-week high $5.63 and $21.53. With a market capitalization of about $2.22 billion, Day One Biopharmaceuticals, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~-1.75). Key stats such as the average daily volume over the past year has been around 4.01 million shares, volume is running light vs its 52-week average. Headquartered in Brisbane, CA, Day One Biopharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jeremy Bender, the company employs approximately 181 people and listed since May 27, 2021. Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers.

Day One Biopharmaceuticals, Inc. generated EPS of -$1.04 over the past year. Five-year average earnings growth is -9.72%. The latest quarter delivered EPS of -$0.35. The next quarter is forecast at -$0.28. Next year's EPS is expected at -$0.12. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 7 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $34.00 to $16.00. The high target offers 57.92% upside. The low target suggests -25.69% downside. The mean target is $24.46. This offers 13.61% upside. Day One Biopharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 05, 2026, missed forecasts by 12.9%. The prior quarter beat by 17.65%. Over the last six quarters, Apple has recorded several small beats. These include 97.14% in February 25, 2025.

Our AI price prediction model suggests that Day One Biopharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 12.26%, with price expected at $24.17 by May 06, 2026, within a range of $20.55 to $27.54 3-Month Outlook: Projected fall of -17.19%, reaching $17.83 by July 21, 2026, with a range of $16.34 to $19.60. 1-Year Outlook: Projected loss of -6.6%, with price at $20.11 by April 22, 2027, within a range of $18.72 to $21.42.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) shares are up 29.94% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Day One Biopharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -20.74. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $33.44, suggesting 55.32% upside. Our AI forecast model points to short-term strength (12.26% over two weeks), a medium-term fall (-17.19% over three months), and a longer-term loss (-6.6% over one year), with expected trading ranges indicating moderate volatility.

Day One Biopharmaceuticals, Inc. trades at a P/E ratio of -20.74, slightly below the S&P 500 average, with a price-to-sales ratio of 14.06 and a price-to-book ratio of 5.05 trading at moderately above to book value. The P/FCF stands at -20.68, also below market averages.